Your coverage of Robert Gallo's annual lab meeting (F. Hoke, The Scientist, Nov. 14, 1994, page 1) revealed unmistakably that research based on the HIV theory of AIDS is at a standstill. Ten years after the discovery of what the newspapers call "HIV, the virus that causes AIDS," it is clear that scientists haven't a clue as to what HIV is supposed to be doing to the cells of the immune system. Gallo's own summary said that there are "conflicting views on the question of whether HIV kills T cell
After a decade of futility, HIV scientists are making no progress in explaining how a retrovirus can be killing cells it doesn't infect. How many more years will it take before biomedical science is willing to reconsider a theory that was established by a press conference, and that has generated nothing since but a steady stream of failed predictions?
Phillip E. Johnson
Professor of Law
University of California
Berkeley, Calif. 94720-2499
E-mail: philjohn@garnet.berkeley.edu
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
